NASDAQ:TBIOTranslate Bio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Translate Bio Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.48 +0.25 (+1.76 %) (As of 08/13/2020 04:00 PM ET) Add Compare Share Today's Range$14.25Now: $14.48▼$14.6150-Day Range$14.23MA: $17.92▼$26.6652-Week Range$6.80Now: $14.48▼$28.09Volume1.10 million shsAverage Volume1.06 million shsMarket Capitalization$1.08 billionP/E RatioN/ADividend YieldN/ABeta0.39 ProfileAnalyst RatingsChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media Translate Bio, Inc., a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency. It has a collaboration and license agreement with Sanofi Pasteur Inc. to develop mRNA vaccines for up to five infectious disease pathogens. The company was formerly known as RaNA Therapeutics, Inc. and changed its name to Translate Bio, Inc. in June 2017. Translate Bio, Inc. was founded in 2011 and is headquartered in Lexington, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingTranslate Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $32.67, Translate Bio has a potential upside of 125.6% from its current price of $14.48.Amount of Analyst CoverageTranslate Bio has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.7 Community Rank Outperform VotesTranslate Bio has received 100 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTranslate Bio has received 188 “underperform” votes. (Add your “underperform” vote.)Community SentimentTranslate Bio has received 65.28% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Translate Bio and other stocks. Vote “Outperform” if you believe TBIO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TBIO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTranslate Bio does not currently pay a dividend.Dividend GrowthTranslate Bio does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Translate Bio insiders have sold 1,209.88% more of their company's stock than they have bought. Specifically, they have bought $11,000,000.00 in company stock and sold $144,086,787.00 in company stock.Percentage Held by InsidersOnly 12.30% of the stock of Translate Bio is held by insiders.Percentage Held by Institutions83.92% of the stock of Translate Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Translate Bio are expected to decrease in the coming year, from ($1.40) to ($1.44) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Translate Bio is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Translate Bio is -8.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTranslate Bio has a P/B Ratio of 5.66. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 1.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.44 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TBIO Previous Symbol CUSIPN/A CIKN/A Webwww.translate.bio Phone617-945-7361Debt Debt-to-Equity Ratio0.08 Current Ratio4.12 Quick Ratio4.12Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$7.80 million Price / Sales137.83 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book5.66Profitability EPS (Most Recent Fiscal Year)($1.84) Net Income$-113,290,000.00 Net Margins-393.56% Return on Equity-64.57% Return on Assets-31.13%Miscellaneous Employees81 Outstanding Shares74,244,000Market Cap$1.08 billion Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $14.48 +0.25 (+1.76 %) (As of 08/13/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive TBIO News and Ratings via Email Sign-up to receive the latest news and ratings for TBIO and its competitors with MarketBeat's FREE daily newsletter. Translate Bio (NASDAQ:TBIO) Frequently Asked Questions How has Translate Bio's stock been impacted by Coronavirus (COVID-19)? Translate Bio's stock was trading at $7.43 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, TBIO stock has increased by 94.9% and is now trading at $14.48. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Translate Bio? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Translate Bio in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Translate Bio. When is Translate Bio's next earnings date? Translate Bio is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Translate Bio. How were Translate Bio's earnings last quarter? Translate Bio Inc (NASDAQ:TBIO) issued its quarterly earnings results on Wednesday, July, 31st. The company reported ($0.57) EPS for the quarter, missing the Zacks' consensus estimate of ($0.48) by $0.09. The business earned $1.17 million during the quarter, compared to the consensus estimate of $1.73 million. Translate Bio had a negative return on equity of 64.57% and a negative net margin of 393.56%. View Translate Bio's earnings history. What price target have analysts set for TBIO? 7 analysts have issued 12-month target prices for Translate Bio's shares. Their forecasts range from $29.00 to $40.00. On average, they expect Translate Bio's share price to reach $32.67 in the next year. This suggests a possible upside of 125.6% from the stock's current price. View analysts' price targets for Translate Bio. Has Translate Bio been receiving favorable news coverage? Press coverage about TBIO stock has trended extremely negative on Thursday, according to InfoTrie Sentiment. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Translate Bio earned a daily sentiment score of -4.1 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news about Translate Bio. Are investors shorting Translate Bio? Translate Bio saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,060,000 shares, an increase of 119.5% from the June 15th total of 1,850,000 shares. Based on an average trading volume of 1,590,000 shares, the short-interest ratio is presently 2.6 days. View Translate Bio's Short Interest. Who are some of Translate Bio's key competitors? Some companies that are related to Translate Bio include Iovance Biotherapeutics (IOVA), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Ablynx (ABLYF), Relay Therapeutics (RLAY), Sorrento Therapeutics (SRNE), Momenta Pharmaceuticals (MNTA), Denali Therapeutics (DNLI), Fate Therapeutics (FATE), Twist Bioscience (TWST), Immunovant (IMVT), Legend Biotech (PCVX), SpringWorks Therapeutics (SWTX), Editas Medicine (EDIT) and Mesoblast (MESO). View all competitors. What other stocks do shareholders of Translate Bio own? Based on aggregate information from My MarketBeat watchlists, some companies that other Translate Bio investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Novavax (NVAX), Moderna (MRNA), NVIDIA (NVDA), Dynavax Technologies (DVAX), Vaxart (VXRT), Johnson & Johnson (JNJ) and Heat Biologics (HTBX). Who are Translate Bio's key executives? Translate Bio's management team includes the following people: Mr. Ronald C. Renaud Jr., Pres, CEO & Director (Age 50)Dr. Michael W. Heartlein, Chief Technology Officer (Age 60)Mr. John R. Schroer C.F.A., CFA, CFO & Treasurer (Age 54)Dr. Richard Wooster, Chief Scientific Officer (Age 59)Mr. Paul D. Burgess J.D., Chief Legal Officer & Corp. Sec. (Age 45) When did Translate Bio IPO? (TBIO) raised $100 million in an IPO on Thursday, June 28th 2018. The company issued 7,700,000 shares at $12.00-$14.00 per share. Citigroup, Leerink Partners and Evercore ISI served as the underwriters for the IPO. What is Translate Bio's stock symbol? Translate Bio trades on the NASDAQ under the ticker symbol "TBIO." Who are Translate Bio's major shareholders? Translate Bio's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (10.55%), Federated Hermes Inc. (3.58%), Goldman Sachs Group Inc. (0.39%), Monashee Investment Management LLC (0.34%), Bank of New York Mellon Corp (0.29%) and EAM Investors LLC (0.17%). Company insiders that own Translate Bio stock include Baupost Group Llc/Ma and Human Genetic Therapies Shire. View institutional ownership trends for Translate Bio. Which institutional investors are selling Translate Bio stock? TBIO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Virtus ETF Advisers LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd.. View insider buying and selling activity for Translate Bio. Which institutional investors are buying Translate Bio stock? TBIO stock was acquired by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Monashee Investment Management LLC, Goldman Sachs Group Inc., EAM Investors LLC, Bessemer Group Inc., Trexquant Investment LP, Bank of New York Mellon Corp, and TD Asset Management Inc.. View insider buying and selling activity for Translate Bio. How do I buy shares of Translate Bio? Shares of TBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Translate Bio's stock price today? One share of TBIO stock can currently be purchased for approximately $14.48. How big of a company is Translate Bio? Translate Bio has a market capitalization of $1.08 billion and generates $7.80 million in revenue each year. The company earns $-113,290,000.00 in net income (profit) each year or ($1.84) on an earnings per share basis. Translate Bio employs 81 workers across the globe. What is Translate Bio's official website? The official website for Translate Bio is www.translate.bio. How can I contact Translate Bio? Translate Bio's mailing address is 29 HARTWELL AVENUE, LEXINGTON MA, 02421. The company can be reached via phone at 617-945-7361. This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
